文献速递系统性红斑狼疮

靶向蛋白激酶CK2抑制剂CX-4945通过调节中性粒细胞浸润及NET形成改善狼疮肾炎

Therapeutic Targeting Protein Kinase CK2 Ameliorates Lupus Nephritis by Modulating Neutrophil Infiltration and Neutrophil Extracellular Trap Formation.
PubMed 文献 · Arthritis Rheumatol · 2026-05-06

本研究在MRL/lpr和IMQ诱导的狼疮小鼠模型中验证蛋白激酶CK2抑制剂CX-4945的治疗作用,并探讨其机制。CX-4945显著改善肾损伤,减少尿白蛋白/肌酐比值、肾小球异常、免疫复合物/C3沉积及中性粒细胞浸润。SLE患者中性粒细胞CK2α表达和酶活性升高,CX-4945通过抑制干扰素刺激基因、ROS相关通路、JNK/p38 MAPK磷酸化及改变NET蛋白组成发挥抗炎作用。

要点

  • CX-4945在狼疮小鼠模型中改善肾损害和中性粒细胞浸润。
  • SLE患者中性粒细胞CK2α表达及酶活性升高。
  • CX-4945抑制JNK/p38 MAPK并改变NET蛋白组成。

核心结论

  • CK2α在SLE中性粒细胞中异常上调,靶向CK2的CX-4945在SLE中发挥治疗效应。
  • CK2是SLE的新治疗靶点,支持CX-4945重定位用于中性粒细胞驱动的炎症和自身免疫病。

研究设计与样本

  • 研究将CX-4945给予多种小鼠模型,包括MRL/lpr小鼠、IMQ诱导狼疮模型、IMQ诱导银屑病模型和盲肠结扎穿刺诱导脓毒症模型。
  • 评估肾功能、组织病理学改变、免疫复合物沉积、NET形成和炎性细胞因子水平。

主要发现

  • CX-4945显著改善MRL/lpr和IMQ诱导狼疮模型的肾损伤,表现为尿白蛋白/肌酐比值降低、肾小球异常减少、免疫复合物/C3沉积减少及中性粒细胞浸润减少。
  • SLE患者中性粒细胞显示CK2α表达和酶活性升高。
  • 机制上,CX-4945抑制干扰素刺激基因和活性氧相关通路,诱导线粒体代谢重编程,抑制JNK/p38 MAPK磷酸化,并改变NET蛋白组成以消除巨噬细胞促炎反应。

关键数值与推荐

  • 原文未报告具体数值、阈值、剂量、样本量或P值。

临床怎么用

  • CX-4945可能作为SLE尤其是狼疮肾炎的潜在治疗药物,通过靶向中性粒细胞CK2发挥作用。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Systemic lupus erythematosus (SLE) is a complex autoimmune disease driven by neutrophil dysregulation and neutrophil extracellular trap (NET) formation, with unmet therapeutic needs. This study aimed to investigate the therapeutic potential of protein kinase CK2 inhibitor CX-4945 in SLE as well as to elucidate the underlying mechanisms. METHODS: CX-4945 was administered to multiple murine models, including MRL/lpr mice, imiquimod (IMQ)-induced lupus model, IMQ-induced psoriasis model, and cecal ligation and puncture-induced sepsis model. Renal function, histopathological changes, immune complex deposition, NET formation, and inflammatory cytokine levels were evaluated. RESULTS: CX-4945 significantly ameliorated renal damage in MRL/lpr and IMQ-induced lupus models, as evidenced by reduced urinary albumin-to-creatinine ratio, glomerular abnormalities, immune complex/complement C3 deposition, and neutrophil infiltration. The neutrophils from patients with SLE exhibited elevated CK2α expression and enzyme activity. Mechanistically, CX-4945 suppressed interferon-stimulated genes and reactive oxygen species-related pathways, induced mitochondrial metabolic rewiring, inhibited JNK/p38 MAPK phosphorylation, and modified NET protein composition to abrogate macrophage proinflammatory responses. CONCLUSION: CK2α is aberrantly up-regulated in SLE neutrophils, and targeting CK2 with CX-4945 exerts therapeutic effects in SLE. These findings identify CK2 as a novel therapeutic target for SLE and support the repurposing of CX-4945 for treating neutrophil-driven inflammatory and autoimmune diseases.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Zhan M, Dong S, Bai Z, et al. Therapeutic Targeting Protein Kinase CK2 Ameliorates Lupus Nephritis by Modulating Neutrophil Infiltration and Neutrophil Extracellular Trap Formation. Arthritis Rheumatol. 2026. PMID: 42087809. doi:10.1002/art.70206

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。